April 19, 2024
An Open-Label Phase 1a/1b Dose Escalation and Expansion Cohort Study of SL-172154 (SIRPα-Fc-CD40L) in Combination With Azacitidine or With Azacitidine and Venetoclax for the Treatment of Subjects With Higher- Risk Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML)
Select an appointment date and time from available spots listed below.